静脉铁剂治疗化疗相关贫血:韩国前瞻性II期试点临床试验
该研究为韩国单中心前瞻性单臂II期试验,评估无促红细胞生成素情况下静脉羧基麦芽糖铁(1000 mg)治疗实体瘤贫血的疗效。92例可分析患者中,第3、5、8周血红蛋白应答率分别为39.1%、57.6%、66.3%,平均升高1.77 g/dL;基线铁调素是应答的独立预测因素。
要点
- 静脉羧基麦芽糖铁1000 mg单药可提升癌症患者血红蛋白,未见严重不良事件。
- 第8周血红蛋白应答率达66.3%,平均升高1.77 g/dL。
- 基线铁调素较低者更可能从铁剂治疗中获益。
核心结论
- 静脉羧基麦芽糖铁(1000 mg)单药治疗可提高癌症患者血红蛋白水平且无严重不良事件。
- 铁调素是预测癌症患者铁需求的可用生物标志物。
研究设计与样本
- 前瞻性单臂II期临床试验,2015年4月至2017年7月在韩国三星医疗中心入组实体瘤患者。
- 共招募103例,92例符合分析条件;中位年龄57.3±12.5岁,女性占54.3%。
- 患者于治疗第1天(第1次访视)接受静脉羧基麦芽糖铁1000 mg输注。
主要发现
- 第3、5、8周血红蛋白应答人数分别为36例(39.1%)、53例(57.6%)、61例(66.3%)。
- 从基线至治疗结束血红蛋白平均升高1.77±1.30 g/dL。
- 应答者基线铁调素显著低于非应答者(13.45±14.71 vs 35.22±40.47 ng/ml,p=0.007)。
- 多因素logistic回归显示仅基线铁调素与血红蛋白应答显著相关(OR=0.95,95%CI 0.90-1.0,p=0.045)。
- 基线铁调素(p=0.008)、总铁结合力(p=0.014)、铁蛋白(p=0.048)和CRP(p=0.044)在应答与非应答组间差异显著。
关键数值与推荐
- 血红蛋白应答定义:8周观察期内(第3、6或8周)血红蛋白较基线升高≥1.0 g/dL、血红蛋白≥11.0 g/dL或两者兼具。
临床怎么用
- 对化疗相关贫血的实体瘤患者,可考虑静脉羧基麦芽糖铁1000 mg单药治疗替代促红细胞生成素。
- 治疗前检测基线铁调素有助于筛选可能从铁剂治疗中获益的患者。
局限性
- 单臂设计,不同研究间患者特征存在差异。
- 铁调素检测存在机构间差异。
- 缺乏长期安全性数据。
- 研究结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anemia is the most common and serious cancer-related complication. This study aimed to evaluate the efficacy of administration of ferric carboxymaltose without erythropoiesis-stimulating agents for treating anemia in cancer patients. Moreover, we identified the biomarkers of hemoglobin response to predict the need for iron therapy. METHODS AND FINDINGS: We enrolled patients with solid cancers who were treated at a single institute (Samsung Medical Center, South Korea), from April 2015 to July 2017, in this prospective single-arm Phase II clinical trial. Patients received intravenous ferric carboxymaltose (1,000 mg) infusion on the first day (visit 1) of treatment. The primary end point was the number of hemoglobin responders, defined as patients with an increase in hemoglobin level ≥ 1.0 g/dL from the baseline, a hemoglobin level ≥ 11.0 g/dL, or both, within an 8-week observation period (week 3, 6, or 8). Secondary end points included changes in transferrin saturation and levels of soluble transferrin receptors, hepcidin, erythropoietin, interleukin-6, and C-reactive protein (CRP) at each visit. Of the 103 recruited patients, 92 were eligible for analysis. The mean patient age was 57.3 ± 12.5 years, and 54.3% of the patients were women. The most common diagnoses were breast cancer (n = 23, 25.1%), lung cancer (n = 21, 22.9%), gastrointestinal cancer (n = 20, 20.9%), and lymphoma (n = 16, 17.7%). A hemoglobin response was observed in 36 (39.1%), 53 (57.6%), and 61 (66.3%) patients in the third, fifth, and eighth weeks, respectively. The mean increase in hemoglobin levels from the baseline to the end of treatment was 1.77 ± 1.30 g/dL. Baseline values of hepcidin (p = 0.008), total iron binding capacity (p = 0.014), ferritin (p = 0.048), and CRP (p = 0.044) were significantly different between the responder and nonresponder groups. Multiple logistic regression analysis for baseline anemia-related biochemical variable significantly associated with the hemoglobin response showed that only baseline hepcidin level was a significant factor for hemoglobin response (odds ratio = 0.95, 95% confidence interval 0.90-1.0, p = 0.045). Hemoglobin responders had significantly lower hepcidin levels than nonresponders (mean [±standard deviation], 13.45 [±14.71] versus 35.22 [±40.470 ng/ml]; p = 0.007). However, our analysis had some limitations such as the different patient characteristics in the studies that were included, institutional differences in the measurement of hepcidin level, and missing data on long-term safety. Therefore, our findings need further validation. CONCLUSIONS: Intravenous ferric carboxymaltose (1,000 mg) monotherapy increases hemoglobin levels without serious adverse events in patients with cancer. Hepcidin is a useful biomarker for predicting iron requirement in cancer patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT02599012.
引用
- Jang JH, Kim Y, Park S, et al. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Med. 2020. PMID: 32511251. doi:10.1371/journal.pmed.1003091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。